Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of urea cycle disorders.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zevra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition November 20, 2023
Details:
Through the acquisition, Zevra will expand its rare disease portfolio and adding commercial product including the recent U.S. commercial approval Olpruva (sodium phenylbutyrate) for the treatment of UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zevra Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 31, 2023
Details:
Under the terms of the new agreement, Acer will reacquire worldwide development, commercialization and economic rights to OLPRUVA™ (sodium phenylbutyrate) from Relief Therapeutics, excluding the European Union. OLPRUVA™ is approved in the U.S. for treatment of UCDs.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Relief Therapeutics
Deal Size: $56.5 million Upfront Cash: $11.5 million
Deal Type: Licensing Agreement August 30, 2023
Details:
The financing will be used for the launch of company's Olpruva (sodium phenylbutyrate), an oral suspension, for the treatment of various disorders, including Maple Syrup Urine Disease (MSUD).
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Christopher Schelling
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 26, 2023
Details:
Olpruva (sodium phenylbutyrate) active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ACER-801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 17, 2023
Details:
Olpruva (sodium phenylbutyrate)active metabolite is phenylacetate which conjugates with glutamine to form phenylacetylglutamine. Phenylacetylglutamine is excreted by the kidneys, hence providing an alternate vehicle for waste nitrogen excretion.
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: ACER-801
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 13, 2023
Details:
ACER-801 (osanetant) is an investigational, novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist currently being evaluated as a potential treatment option for men with adenocarcinoma of the prostate.
Lead Product(s): Osanetant
Therapeutic Area: Oncology Product Name: ACER-801
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2023
Details:
OLPRUVA™ (sodium phenylbutyrate), is an oral suspension prescription medicine used for the treatment of rare, genetic disorders like Urea cycle disorders (UCDs) .
Lead Product(s): Sodium Phenylbutyrate
Therapeutic Area: Genetic Disease Product Name: Olpruva
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Relief Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2022